Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs ...

You've just been diagnosed with HER2+ breast cancer ... use include ado-trastuzumab emtansine (Kadcyla), fam-trastuzumab deruxtecan (Enhertu), lapatinib, margetuximab, pertuzumab, and tucatinib.

After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...

The UK health technology assessment (HTA) agency has backed Enhertu (trastuzumab deruxtecan) as a therapy for HER2 positive breast cancer which can’t be surgically removed or which has spread to ...

Dato-DXd: Daiichi Sankyo, Inc. Datopotamab deruxtecan (Dato-DXd) is an investigational currently in Phase III for HR-positive ...

Daiichi Sankyo has entered into an exclusive licence agreement worth up to $300m with Alteogen to develop a subcutaneous ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

T-Duo is a third-generation HER2-targeted antibody-drug conjugate designed to treat HER2–positive breast cancer ... previously treated with trastuzumab deruxtecan. This study was supported ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...